Geron Corporation

NasdaqGS GERN

Geron Corporation Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2024: -61.83%

Geron Corporation Return on Capital Employed (ROCE) is -61.83% for the Trailing 12 Months (TTM) ending September 30, 2024, a -7.62% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Geron Corporation Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -57.46%, a 22.79% change year over year.
Geron Corporation Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2022 was -74.41%, a -55.82% change year over year.
Geron Corporation Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2021 was -47.76%, a -13.55% change year over year.
Geron Corporation Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2020 was -42.06%.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NasdaqGS: GERN

Geron Corporation

CEO	Dr. John A. Scarlett M.D.
IPO Date	July 31, 1996
Location	United States
Headquarters	919 East Hillsdale Boulevard
Employees	141
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Key trends

Past 5 years